Personalized [177Lu]Lutetium-PSMA Therapy for Patients with Pre-Treated Castration-Resistant Prostate Cancer: A Single Institution Experience from a Comprehensive Cancer Centre

SIMPLE SUMMARY: Advanced prostate cancer can be treated with [177Lu]-Lutetium-PSMA radi-oligand therapy (Lu-PSMA) in advanced stages. However, little is known about the predictive factors for treatment success. We retrospectively analyzed Lu-PSMA radioligand treatments in 86 patients. The focus of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Thaiss, Wolfgang, Zengerling, Friedemann, Friedrich, Julia, Hechler, Veronika, Grunert, Michael, Bolenz, Christian, Wiegel, Thomas, Beer, Ambros J., Prasad, Vikas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296825/
https://www.ncbi.nlm.nih.gov/pubmed/37370826
http://dx.doi.org/10.3390/cancers15123216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296825/
https://www.ncbi.nlm.nih.gov/pubmed/37370826
http://dx.doi.org/10.3390/cancers15123216

Ejemplares similares